HRP20100376T1 - Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja - Google Patents
Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja Download PDFInfo
- Publication number
- HRP20100376T1 HRP20100376T1 HR20100376T HRP20100376T HRP20100376T1 HR P20100376 T1 HRP20100376 T1 HR P20100376T1 HR 20100376 T HR20100376 T HR 20100376T HR P20100376 T HRP20100376 T HR P20100376T HR P20100376 T1 HRP20100376 T1 HR P20100376T1
- Authority
- HR
- Croatia
- Prior art keywords
- pipamperone
- serotonin
- antagonist
- pharmaceutically acceptable
- administered
- Prior art date
Links
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 title claims abstract 11
- 229960002776 pipamperone Drugs 0.000 title claims abstract 10
- 239000002464 receptor antagonist Substances 0.000 title claims abstract 7
- 229940044551 receptor antagonist Drugs 0.000 title claims abstract 7
- 208000028017 Psychotic disease Diseases 0.000 title claims abstract 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 229940076279 serotonin Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 101150049660 DRD2 gene Proteins 0.000 claims abstract 6
- 239000013543 active substance Substances 0.000 claims abstract 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims abstract 3
- 229940127236 atypical antipsychotics Drugs 0.000 claims 8
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 claims 4
- 229950009087 bifeprunox Drugs 0.000 claims 4
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 3
- -1 SL 91.0177 Chemical compound 0.000 claims 3
- 229960001057 paliperidone Drugs 0.000 claims 3
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims 2
- 229960005245 asenapine Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960005197 quetiapine fumarate Drugs 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229960000652 sertindole Drugs 0.000 claims 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 claims 1
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims 1
- 229960003036 amisulpride Drugs 0.000 claims 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 229950002871 blonanserin Drugs 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960003162 iloperidone Drugs 0.000 claims 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 1
- 229960001432 lurasidone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229950010634 ocaperidone Drugs 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229950004193 perospirone Drugs 0.000 claims 1
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03447279A EP1547650A1 (en) | 2003-12-02 | 2003-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US10/725,965 US7884096B2 (en) | 2003-12-02 | 2003-12-02 | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA2451798A CA2451798C (en) | 2003-12-02 | 2003-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP04447001 | 2004-01-05 | ||
| US10/752,423 US7855195B2 (en) | 2003-12-02 | 2004-01-06 | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US10/803,793 US20050119249A1 (en) | 2003-12-02 | 2004-03-18 | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP04447066A EP1576985A1 (en) | 2004-03-18 | 2004-03-18 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA 2461248 CA2461248C (en) | 2003-12-02 | 2004-03-18 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| EP04025035A EP1541197B8 (en) | 2003-12-02 | 2004-10-21 | Use of pipamperone and an SNDRI, SNRI or SSRI for the treatment of mood or anxiety disorders |
| JP2004349085A JP4571485B2 (ja) | 2003-12-02 | 2004-11-04 | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 |
| US10/984,683 US20050203130A1 (en) | 2003-12-02 | 2004-11-09 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CA 2487529 CA2487529A1 (en) | 2003-12-02 | 2004-11-15 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| PCT/BE2004/000172 WO2005053796A1 (en) | 2003-12-02 | 2004-12-02 | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100376T1 true HRP20100376T1 (hr) | 2010-08-31 |
Family
ID=42134278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100376T HRP20100376T1 (hr) | 2003-12-02 | 2010-07-06 | Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | ATE464901T1 (sl) |
| DE (1) | DE602004026781D1 (sl) |
| DK (1) | DK1708790T3 (sl) |
| ES (1) | ES2343962T3 (sl) |
| HR (1) | HRP20100376T1 (sl) |
| PT (1) | PT1708790E (sl) |
| RS (1) | RS51331B (sl) |
| SI (1) | SI1708790T1 (sl) |
-
2004
- 2004-12-02 RS RSP-2010/0323A patent/RS51331B/en unknown
- 2004-12-02 DE DE602004026781T patent/DE602004026781D1/de active Active
- 2004-12-02 DK DK04801138.1T patent/DK1708790T3/da active
- 2004-12-02 SI SI200431439T patent/SI1708790T1/sl unknown
- 2004-12-02 AT AT04801138T patent/ATE464901T1/de active
- 2004-12-02 PT PT04801138T patent/PT1708790E/pt unknown
- 2004-12-02 ES ES04801138T patent/ES2343962T3/es active Active
-
2010
- 2010-07-06 HR HR20100376T patent/HRP20100376T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE464901T1 (de) | 2010-05-15 |
| DK1708790T3 (da) | 2010-06-21 |
| SI1708790T1 (sl) | 2010-09-30 |
| DE602004026781D1 (de) | 2010-06-02 |
| RS51331B (en) | 2011-02-28 |
| ES2343962T3 (es) | 2010-08-13 |
| PT1708790E (pt) | 2010-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1755561B1 (en) | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines | |
| ES2231221T3 (es) | Tableta multicapa para la administracion de una combinacion fija de tramadol y de diclofenac. | |
| ES2623503T3 (es) | Composiciones para tratar náuseas y vómitos mediados centralmente | |
| TWI426906B (zh) | 治療精神分裂症的醫藥組成物 | |
| US20060211686A1 (en) | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | |
| WO2006096439A2 (en) | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases | |
| US20120157472A1 (en) | Method for treating colorectal cancer | |
| US9622979B2 (en) | Multilayered dosage form | |
| WO2004080444A2 (en) | Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators | |
| CN101069675A (zh) | 用于减轻痉挛状态的体征和症状的方法 | |
| JP2010539184A (ja) | 投薬レジメン | |
| KR20170007868A (ko) | Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 | |
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| WO2007086079A3 (en) | Sustained release dosage form of phenothiazine derivatives containing channelizer | |
| EP0643967A2 (en) | Pharmaceutical compositions containing analgesic, e.g. morphine, and a laxative, e.g. bisacodyl | |
| JP2016505050A5 (sl) | ||
| JP2006528604A5 (sl) | ||
| HRP20100376T1 (hr) | Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja | |
| BRPI0908988A2 (pt) | formulação galênica oral incluindo cetorolaco e vitaminas do complexo b, em que a vitamina b6 está em uma camada externa separada do resto dos princípios ativos | |
| RU2005135649A (ru) | Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги | |
| ES2285088T3 (es) | Composiciones farmaceuticas de liberacion modificada. | |
| AU2004273605B2 (en) | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| AU2018367733B2 (en) | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia | |
| CN114432446B (zh) | 抗组胺药在制备抗肿瘤药物中的应用 |